Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. Co.'s commercial medicines are: SPINRAZA, a survival motor neuron-2, directed antisense medicine for the treatment of spinal muscular atrophy in pediatric and adult patients; TEGSEDI, an RNA-targeted medicine designed to reduce the production of TTR protein; and WAYLIVRA, an antisense medicine designed to treat people with rare, hereditary diseases. Co. has drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for various forms of TTR amyloidosis. The IONS stock yearly return is shown above.
The yearly return on the IONS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IONS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|